Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</title><author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</nlm:aff></affiliation><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author><author><name sortKey="Morris, John C" sort="Morris, John C" uniqKey="Morris J" first="John C." last="Morris">John C. Morris</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</nlm:aff></affiliation></author><author><name sortKey="Stewart, Donn M" sort="Stewart, Donn M" uniqKey="Stewart D" first="Donn M." last="Stewart">Donn M. Stewart</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Urquhart, Nicole E" sort="Urquhart, Nicole E" uniqKey="Urquhart N" first="Nicole E." last="Urquhart">Nicole E. Urquhart</name><affiliation><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff></affiliation></author><author><name sortKey="Janik, John E" sort="Janik, John E" uniqKey="Janik J" first="John E." last="Janik">John E. Janik</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Kreitman, Robert J" sort="Kreitman, Robert J" uniqKey="Kreitman R" first="Robert J." last="Kreitman">Robert J. Kreitman</name><affiliation><nlm:aff wicri:cut=", and" id="aff6">Clinical Immunotherapy Section, Laboratory of Molecular Biology</nlm:aff></affiliation></author><author><name sortKey="Lita, Elena" sort="Lita, Elena" uniqKey="Lita E" first="Elena" last="Lita">Elena Lita</name><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author><author><name sortKey="Conlon, Kevin" sort="Conlon, Kevin" uniqKey="Conlon K" first="Kevin" last="Conlon">Kevin Conlon</name><affiliation><nlm:aff id="aff7">Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</nlm:aff></affiliation></author><author><name sortKey="Wharfe, Gilian" sort="Wharfe, Gilian" uniqKey="Wharfe G" first="Gilian" last="Wharfe">Gilian Wharfe</name><affiliation><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff></affiliation></author><author><name sortKey="Waldmann, Thomas A" sort="Waldmann, Thomas A" uniqKey="Waldmann T" first="Thomas A." last="Waldmann">Thomas A. Waldmann</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Kaushal, Aradhana" sort="Kaushal, Aradhana" uniqKey="Kaushal A" first="Aradhana" last="Kaushal">Aradhana Kaushal</name><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22730536</idno><idno type="pmc">3433088</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433088</idno><idno type="RBID">PMC:3433088</idno><idno type="doi">10.1182/blood-2012-01-401349</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000272</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000272</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</title><author><name sortKey="Simone, Charles B" sort="Simone, Charles B" uniqKey="Simone C" first="Charles B." last="Simone">Charles B. Simone</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</nlm:aff></affiliation><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author><author><name sortKey="Morris, John C" sort="Morris, John C" uniqKey="Morris J" first="John C." last="Morris">John C. Morris</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</nlm:aff></affiliation></author><author><name sortKey="Stewart, Donn M" sort="Stewart, Donn M" uniqKey="Stewart D" first="Donn M." last="Stewart">Donn M. Stewart</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Urquhart, Nicole E" sort="Urquhart, Nicole E" uniqKey="Urquhart N" first="Nicole E." last="Urquhart">Nicole E. Urquhart</name><affiliation><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff></affiliation></author><author><name sortKey="Janik, John E" sort="Janik, John E" uniqKey="Janik J" first="John E." last="Janik">John E. Janik</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Kreitman, Robert J" sort="Kreitman, Robert J" uniqKey="Kreitman R" first="Robert J." last="Kreitman">Robert J. Kreitman</name><affiliation><nlm:aff wicri:cut=", and" id="aff6">Clinical Immunotherapy Section, Laboratory of Molecular Biology</nlm:aff></affiliation></author><author><name sortKey="Lita, Elena" sort="Lita, Elena" uniqKey="Lita E" first="Elena" last="Lita">Elena Lita</name><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author><author><name sortKey="Conlon, Kevin" sort="Conlon, Kevin" uniqKey="Conlon K" first="Kevin" last="Conlon">Kevin Conlon</name><affiliation><nlm:aff id="aff7">Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</nlm:aff></affiliation></author><author><name sortKey="Wharfe, Gilian" sort="Wharfe, Gilian" uniqKey="Wharfe G" first="Gilian" last="Wharfe">Gilian Wharfe</name><affiliation><nlm:aff wicri:cut="; and" id="aff5">Department of Pathology, University of the West Indies, Mona, Jamaica</nlm:aff></affiliation></author><author><name sortKey="Waldmann, Thomas A" sort="Waldmann, Thomas A" uniqKey="Waldmann T" first="Thomas A." last="Waldmann">Thomas A. Waldmann</name><affiliation><nlm:aff id="aff3">Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</nlm:aff></affiliation></author><author><name sortKey="Kaushal, Aradhana" sort="Kaushal, Aradhana" uniqKey="Kaushal A" first="Aradhana" last="Kaushal">Aradhana Kaushal</name><affiliation><nlm:aff wicri:cut=" and" id="aff2">Radiation Oncology Branch</nlm:aff></affiliation></author></analytic><series><title level="j">Blood</title><idno type="ISSN">0006-4971</idno><idno type="eISSN">1528-0020</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; <italic>P</italic> = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control across ATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.</p></div></front></TEI><pmc article-type="brief-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Blood</journal-id><journal-id journal-id-type="iso-abbrev">Blood</journal-id><journal-id journal-id-type="hwp">bloodjournal</journal-id><journal-id journal-id-type="pmc">blood</journal-id><journal-id journal-id-type="publisher-id">Blood</journal-id><journal-title-group><journal-title>Blood</journal-title></journal-title-group><issn pub-type="ppub">0006-4971</issn><issn pub-type="epub">1528-0020</issn><publisher><publisher-name>American Society of Hematology</publisher-name><publisher-loc>Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22730536</article-id><article-id pub-id-type="pmc">3433088</article-id><article-id pub-id-type="publisher-id">2011/401349</article-id><article-id pub-id-type="doi">10.1182/blood-2012-01-401349</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials and Observations</subject></subj-group><subj-group subj-group-type="leader"><subject>Brief Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Lymphoid Neoplasia</subject></subj-group></article-categories><title-group><article-title>Radiation therapy for the management of patients with HTLV-1–associated adult T-cell leukemia/lymphoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Simone</surname><given-names>Charles B.</given-names><suffix>II</suffix></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Donn M.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Urquhart</surname><given-names>Nicole E.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Janik</surname><given-names>John E.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kreitman</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lita</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Conlon</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Wharfe</surname><given-names>Gilian</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Waldmann</surname><given-names>Thomas A.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kaushal</surname><given-names>Aradhana</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><aff id="aff1"><label>1</label>Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA;</aff><aff id="aff2"><label>2</label>Radiation Oncology Branch and</aff><aff id="aff3"><label>3</label>Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD;</aff><aff id="aff4"><label>4</label>Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH;</aff><aff id="aff5"><label>5</label>Department of Pathology, University of the West Indies, Mona, Jamaica; and</aff><aff id="aff6"><label>6</label>Clinical Immunotherapy Section, Laboratory of Molecular Biology, and</aff><aff id="aff7"><label>7</label>Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD</aff></contrib-group><pub-date pub-type="ppub"><day>30</day><month>8</month><year>2012</year></pub-date><pub-date pub-type="epreprint"><day>22</day><month>6</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>8</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 12 months and 0 days and was based on the
<volume>120</volume><issue>9</issue><fpage>1816</fpage><lpage>1819</lpage><history><date date-type="received"><day>7</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>6</day><month>6</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 by The American Society of Hematology</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zh803512001816.pdf"></self-uri><abstract><p>Human T-cell leukemia virus type 1–associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; <italic>P</italic> = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control across ATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.</p></abstract><funding-group><award-group><funding-source id="CS100">National Institutes of Health</funding-source></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0002720 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0002720 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= CobaltMaghrebV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |